Characterization of hepatocellular carcinoma related genes and metabolites in human nonalcoholic fatty liver disease

Digestive Diseases and Sciences

Volumn 59, Issue 2, 2014, Pages 365-374

  Clarke, John D ^a   Novak, Petr ^a,b   Lake, April D ^a   Shipkova, Petia ^c   Aranibar, Nelly ^c   Robertson, Donald ^c   Severson, Paul L ^a   Reily, Michael D ^c   Futscher, Bernard W ^a   Lehman Mckeeman, Lois D ^c   Cherrington, Nathan J ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b INSTITUTE OF PLANT MOLECULAR BIOLOGY   (Czech Republic)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Hepatocellular carcinoma; Metabolomics; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis

Indexed keywords

ALPHA3 INTEGRIN; ANGIOPOIETIN 2; BIOLOGICAL MARKER; CERULOPLASMIN; COLLAGEN TYPE 1 ALPHA 2; CYBRD1 PROTEIN; FERROPORTIN 1; HEPCIDIN; MATRIX METALLOPROTEINASE 14; MEROSIN; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG; WNT PROTEIN; ZIP14 PROTEIN;

ANGIOGENESIS; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; METABOLITE; METABOLOMICS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; TRANSCRIPTOMICS; UPREGULATION; WNT SIGNALING PATHWAY;

CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; CLUSTER ANALYSIS; DATABASES, GENETIC; FATTY LIVER; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; METABOLOMICS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84896695216     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-013-2873-9     Document Type: Article

References (40)

1. Aigner E, Theurl I, Haufe H, et al. Copper availability contributes to iron perturbations in human nonalcoholic fatty liver disease. Gastroenterology. 2008;135:680-688.
2. Ali R, Cusi K. New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Ann Med. 2009;41:265-278.
3. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in nonalcoholic fatty liver disease: an emerging menace. J Hepatol. 2012;56:1384-1391.
4. Benjamini Y, Hochberg Y. Controlling the false discovery rate - a practical and powerful approach to multiple testing. J Roy Stat Soc Ser B Method. 1995;57:289-300.
5. Boyault S, Rickman DS, de Reynies A, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology. 2007;45:42-52.
6. Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin Liver Dis. 2007;11:191-207.
7. Cadoret A, Ovejero C, Terris B, et al. New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism. Oncogene. 2002;21:8293-8301.
8. Cavard C, Terris B, Grimber G, et al. Overexpression of regenerating islet-derived 1 alpha and 3 alpha genes in human primary liver tumors with beta-catenin mutations. Oncogene. 2006;25:599-608.
9. Chan DW, Chan CY, Yam JW, Ching YP, Ng IO. Prickle-1 negatively regulates Wnt/beta-catenin pathway by promoting Dishevelled ubiquitination/degradation in liver cancer. Gastroenterology. 2006;131:1218-1227.
10. Chen T, Xie G, Wang X, et al. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol Cell Proteomics. 2011;10:M110.004945-1-13.
11. Coulon S, Heindryckx F, Geerts A, Van Steenkiste C, Colle I, Van Vlierberghe H. Angiogenesis in chronic liver disease and its complications. Liver Int. 2011;31:146-162.
12. Di Bisceglie AM, Lyra AC, Schwartz M, et al. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol. 2003;98:2060-2063.
13. Fisher CD, Lickteig AJ, Augustine LM, et al. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos. 2009;37:2087-2094.
14. Kim M, Lee HC, Tsedensodnom O, et al. Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells. J Hepatol. 2008;48:780-791.
15. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-1321.
16. Lachenmayer A, Alsinet C, Savic R, et al. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by Sorafenib. Clin Cancer Res. 2012;18:4997-5007.
17. Lake AD, Novak P, Fisher CD, et al. Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos. 2011;39:1954-1960.
18. Leonardi GC, Candido S, Cervello M, et al. The tumor microenvironment in hepatocellular carcinoma (review). Int J Oncol. 2012;40:1733-1747.
19. Luo W, Friedman MS, Shedden K, Hankenson KD, Woolf PJ. GAGE: generally applicable gene set enrichment for pathway analysis. BMC Bioinform. 2009;10:161-162.
20. Merle P, de la Monte S, Kim M, et al. Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology. 2004;127:1110-1122.
21. Novak P, Jensen T, Oshiro MM, Watts GS, Kim CJ, Futscher BW. Agglomerative epigenetic aberrations are a common event in human breast cancer. Cancer Res. 2008;68:8616-8625.
22. O'Brien J, Powell LW. Non-alcoholic fatty liver disease: is iron relevant? Hepatol Int. 2011;6:332-341.
23. Pang R, Yuen J, Yuen MF, et al. PIN1 overexpression and beta-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma. Oncogene. 2004;23:4182-4186.
24. Patterson AD, Maurhofer O, Beyoglu D, et al. Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. Cancer Res. 2011;71:6590-6600.
25. Qin X, Zhang H, Zhou X, et al. Proliferation and migration mediated by Dkk-1/Wnt/beta-catenin cascade in a model of hepatocellular carcinoma cells. Transl Res. 2007;150:281-294.
26. Ratziu V, Bonyhay L, Di Martino V, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology. 2002;35:1485-1493.
27. Regimbeau JM, Colombat M, Mognol P, et al. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl. 2004;10:S69-S73.
28. Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer. 2009;115:5651-5661.
29. Smyth GK. Bioinformatics and computational biology solutions using R and bioconductor, in Limma: Linear models for microarray data. New York: Springer; 2011.
30. Sorrentino P, D'Angelo S, Ferbo U, Micheli P, Bracigliano A, Vecchione R. Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. J Hepatol. 2009;50:351-357.
31. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010;51:1820-1832.
32. Starmann J, Falth M, Spindelbock W, et al. Gene expression profiling unravels cancer-related hepatic molecular signatures in steatohepatitis but not in steatosis. PLoS One. 2012;7:e46584.
33. Takagi H, Sasaki S, Suzuki H, et al. Frequent epigenetic inactivation of SFRP genes in hepatocellular carcinoma. J Gastroenterol. 2008;43:378-389.
34. Tan MG, Kumarasinghe MP, Wang SM, Ooi LL, Aw SE, Hui KM. Modulation of iron-regulatory genes in human hepatocellular carcinoma and its physiological consequences. Exp Biol Med (Maywood). 2009;234:693-702.
35. Thompson MD, Monga SP. WNT/beta-catenin signaling in liver health and disease. Hepatology. 2007;45:1298-1305.
36. Valenti L, Swinkels DW, Burdick L, et al. Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2011;21:568-575.
37. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis. 2007;27:55-76.
38. Yamamoto Y, Sakamoto M, Fujii G, et al. Overexpression of orphan G-protein-coupled receptor, Gpr49, in human hepatocellular carcinomas with beta-catenin mutations. Hepatology. 2003;37:528-533.
39. Yau TO, Chan CY, Chan KL, et al. HDPR1, a novel inhibitor of the WNT/beta-catenin signaling, is frequently downregulated in hepatocellular carcinoma: involvement of methylation-mediated gene silencing. Oncogene. 2005;24:1607-1614.
40. Younossi ZM, Gorreta F, Ong JP, et al. Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis. Liver Int. 2005;25:760-771.